Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John D. Hainsworth, M.D.
SCRI Development Innovations, LLC
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Florida Cancer Specialists
Fort Myers, Florida, United States
- Florida Cancer Specialists
St. Petersburg, Florida, United States
- Oncology Hematology Care, Inc.
Cincinnati, Ohio, United States
- Chattanooga Oncology Hematology Associates
Chattanooga, Tennessee, United States
- Tennessee Oncology, Pllc
Nashville, Tennessee, United States
- Center for Cancer and Blood Disorders
Fort Worth, Texas, United States
- Virginia Cancer Institute
Richmond, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2011
- Primary completion
- 31 Jul 2014
- Completion
- 31 Jul 2014
- Last update posted
- 29 Jan 2016
- Registered enrollment
- 283
- Registry id
- NCT01048099
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.